Red Ginseng for Health & Longevity

Created on 11/10/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Red ginseng, steamed Asian ginseng root sold as a dietary supplement for energy, sexual health and healthy aging, is best understood as a low-risk, low-to-moderate-yield option: the firmest findings concern menopausal symptoms and erectile function, though erection gains are small; other uses rest on mixed or weak evidence. Rarer, more serious concerns include unexpected bleeding, elevated mood episodes, liver injury with certain drugs and low white cell counts during chemotherapy. (Full Review)

Protocol

Standard daily dose
2–3 g/day
Red ginseng powder or extract; range used in fatigue and menopause trials
Erectile function regimen
900–1,000 mg three times daily
For 8–12 weeks
Time of day
Morning or early afternoon
Limits insomnia; before meals suits glucose goals
Time to effect
Erectile function
8–12 weeks
Effects measured after 8 or 12 weeks in trials
Menopausal symptoms
12 weeks
Blood pressure and lipid effects also after 12 weeks
Fatigue
3 weeks
Changes appeared in healthy adults

Benefits

Contraindications
  • Pregnant or breastfeeding women
  • Children and adolescents under 18 years
  • People allergic to ginseng
  • People with bipolar disorder or prior mania
  • Patients taking imatinib
  • People with estrogen-receptor-positive breast or endometrial cancer
  • People with congenital long QT syndrome
Key Interactions
  • Warfarin
  • CYP3A4 substrates (tacrolimus, cyclosporine)
  • Raltegravir
  • Lamotrigine
  • MAOIs (phenelzine)
  • Alcohol
  • Chemotherapy (mFOLFOX-6)
Theoretical (inferred from mechanism)
  • Insulin and sulfonylureas (glipizide, glimepiride)
  • Antihypertensives (amlodipine, lisinopril)
  • Antiplatelet drugs and direct oral anticoagulants (aspirin, apixaban)
  • Stimulants (pseudoephedrine, yohimbine)
  • Supplements lowering glucose or blood pressure (berberine, garlic)
  • Estrogen-modulating therapies (tamoxifen, aromatase inhibitors, hormone therapy)
  • QT-prolonging drugs (sotalol, citalopram)
  • Antidepressants (sertraline, bupropion) and St. John's wort

Risk & Side Effects

  • High:
  • Medium: Neutropenia during chemotherapy
  • Low: Insomnia, nervousness and blood pressure rise; digestive upset; headache; allergic skin reactions; estrogen-like effects; mania; liver injury; bleeding and perioperative coagulopathy; cerebral arteritis; QT interval prolongation and arrhythmia
  • Speculative: Embryo toxicity; growth of hormone-sensitive cancers

Monitoring

Marker Target Why
Blood pressure <120/<80 mmHg Expected to change; safety check if rising
LDL cholesterol Not specified in the ER Expected to change
Fasting glucose 70–99 mg/dL Safety check on glucose-lowering drugs
ALT and AST ALT 7–56 U/L, AST 10–40 U/L Liver safety check
INR (warfarin users only) Stable within the prescribed therapeutic range Anticoagulation safety check
Complete blood count (during chemotherapy only) Absolute neutrophil count 1.5–8.0 × 10⁹/L Neutropenia safety check

Cadence: Baseline before starting; home blood pressure weekly for the first 4 weeks; INR at 1–2 weeks for warfarin users; glucose daily for 2–4 weeks for insulin or sulfonylurea users; then lipids, glucose and liver enzymes at 12 weeks and every 6–12 months during continued use.

Qualitative Assessment

  • Energy and fatigue (a 0–10 daily rating)
  • Sleep quality and sleep onset
  • Erectile function (self-rated with the five-item IIEF)
  • Menopausal symptoms (hot flash frequency and severity)
  • Mood, nervousness or restlessness
  • Any vaginal bleeding or breast changes